Pulmonary arterial hypertension (PAH) drugs market size to grow by USD 2,080.07 million between 2022 and 2027; Growth driven by growing prevalence of PAH - Technavio

NEW YORK, April 18, 2023 /PRNewswire/ -- The pulmonary arterial hypertension (PAH) drugs market size is forecasted to increase by USD 2,080.07 million from 2022 to 2027, at a CAGR of 6.62%, according to the recent market study by Technavio. The growth of the market will be driven by the immunity-boosting properties of herbal medicines, low side effects, and natural healing by using herbal remedies. The comprehensive report includes charts & data tables about market and segment sizes for a historic period (2017-2021) and forecast period (2023-2027). Get a glimpse here. Download the Sample Report

Vendor Analysis

The pulmonary arterial hypertension (PAH) drugs market report includes information on the key products and recent developments of leading vendors, including:

• Aerami Therapeutics Holdings Inc.: The company offers pulmonary arterial hypertension drug solutions such as Orphan. In addition, this segment focuses on developing inhaled therapies to treat severe respiratory and chronic diseases.
• Asklepion Pharmaceuticals LLC: The company offers pulmonary arterial hypertension drug solutions such as IV Citrulline.
• AstraZeneca Plc: The company offers pulmonary arterial hypertension drug solutions such as Mitiperstat.
• Bayer AG: The company offers pulmonary arterial hypertension drug solutions such as Adempas.
• Daiichi Sankyo Co. Ltd.
• Dr Reddys Laboratories Ltd.
• Eiger BioPharmaceuticals Inc.
• Gilead Sciences Inc.
• GlaxoSmithKline Plc
• Johnson and Johnson Services Inc.
• Lupin Ltd.
• Merck and Co. Inc.
• Novartis AG
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
• United Therapeutics Corp.

Why Buy?

• Add credibility to strategy
• Analyzes competitor's offerings
• Get a holistic view of the market

Technavio boosts your profit margin, to know more - Buy the Report

Key Benefits for Industry Players & Stakeholders – 

• The report offers information on the criticality of vendor inputs, including R&D, CAPEX, and technology.
• It also provides detailed analyses of the market's competitive landscape and vendors' product offerings.
• The report also provides a qualitative and quantitative analysis of vendors to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.

Get an extensive market analysis to develop growth strategies. Download the Sample

Market Segmentation:

The market is segmented by administration (oral, injectable, and inhalation), action mechanism (prostacyclin analogs, endothelin receptor antagonists (ERAS), phosphodiesterase (PDE) inhibitors, and soluble guanylate cyclase stimulators (SGCSS)), and geography (North America, Europe, Asia, and Rest of World (ROW)).

By administration, the market growth will be significant in the oral segment during the forecast period. Oral administration includes tablets and suspensions, and tablets can be divided into film-coated tablets and extended-release tablets. The market segment is likely to grow during the forecast period, as these formulations do not require extensive efficacy and safety studies in animals and humans.

By action mechanism, the market growth will be significant in the prostacyclin analog segment during the forecast period. Prostacyclin analogs for PAH are drugs that lower blood pressure in the arteries that carry deoxygenated blood from the heart to the lungs, which is a condition known as PAH. Epoprostenol, iloprost, and treprostinil are examples of prostacyclin analogs used in clinical settings. All three are used to treat PAH, a serious condition that worsens over time and is characterized by vasoconstriction and pulmonary arteriole smooth muscle cell proliferation. Thus, growing treatments related to PAH are expected to drive the growth of the prostacyclin analogs segment in the global PAH drugs market during the forecast period.

North America will account for 45% of the market growth during the forecast period. The growth of the regional market growth is attributed to the advanced healthcare systems in the US and Canada, which facilitate access to innovative treatments. Moreover, increasing awareness, a high diagnosis rate, and favorable government initiatives are boosting market growth in the region. Regional market expansion is also underpinned by well-designed reward structures and the presence of key players. The need for advanced medical facilities to treat pulmonary arterial hypertension is driven by the increasing prevalence and high diagnosis rates of infectious and chronic diseases in this region. 

Market Dynamics:

Key Drivers:

• Growing prevalence of PAH 
• Growing geriatric population 
• Increasing risk factors for cardiovascular diseases 

During the forecast period, the rising prevalence of PAH disease and associated hospitalizations for treatment are expected to boost the demand for related drugs. When PAH occurs, the small arteries in the lungs thicken and narrow. Blood flow through the lungs is blocked by PAHs. This increases blood pressure in the lungs and makes it difficult for the heart to pump blood through the narrowed arteries. The human heart gradually loses its ability to pump blood effectively throughout the body.

Major Trends:

• Increasing awareness regarding PAH 
• Growing technological advancements and new product launches 
• Rising approval of PAH drugs 

The hypertension in the pulmonary arteries, which carry blood from the heart to the lungs, is a hallmark of PAH, a rare and progressive disease. PAH occurs when the pulmonary arteries constrict and become smaller in diameter or become blocked. PAH has become more common in recent years due to increasing risk factors such as HIV, sedentary lifestyles, tobacco and alcohol use, smoking, and other idiopathic diseases. Due to the rising prevalence of PAH globally, market participants will soon have access to opportunities, which will drive the growth of the global PAH drugs market during the forecast period.

Key Challenges:

• Shortage of healthcare professionals
• High costs associated with PAH treatment. 
• Several side effects are associated with PAH drugs   

Factors such as an aging workforce, declining enrollment rates, early retirement, inadequate education, and increased demand from an aging and growing population lead to a shortage of healthcare professionals. Therefore, the shortage of medical professionals could pose a major challenge to the growth of the global PAH drugs market during the forecast period.

Get instant lifetime access to 17,000+ market research reports within MINUTES. 
Technavio's SUBSCRIPTION platform

What are the key data covered in this Pulmonary arterial hypertension (PAH) drugs market report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the growth of the pulmonary arterial hypertension drugs market between 2023 and 2027
• Precise estimation of the size of the pulmonary arterial hypertension drugs market and its contribution to the parent market
• Accurate predictions about upcoming trends and changes in consumer behavior
• Growth of the pulmonary arterial hypertension drugs market across North America, Europe, Asia, and Rest of World (ROW)
• A thorough analysis of the market's competitive landscape and detailed information about vendors
• Comprehensive analysis of factors that will challenge the growth of Pulmonary Arterial Hypertension Drugs Market vendors.

Related Reports: 

• The transcatheter pulmonary valve market size is estimated to grow at a CAGR of 6.1% between 2021 and 2026. The market size is forecasted to increase by USD 51.74 million. The market is segmented by technology (balloon-expanded and self-expanded) and geography (North America, Europe, Asia, and Rest of World (ROW)).
• The pulmonary edema therapeutics market is expected to grow at a CAGR of 3.06% between 2021 and 2026, and the market size is expected to increase by USD 339.45 million. The market is segmented by type (cardiogenic pulmonary edema and non-cardiogenic pulmonary edema) and geography (North America, Europe, Asia, and Rest of World (ROW)).

Browse through Technavio's Health Care Market Reports

Table of contents:

1 Executive Summary

• 1.1 Market overview
• Exhibit 01: Executive Summary – Chart on Market Overview
• Exhibit 02: Executive Summary – Data Table on Market Overview
• Exhibit 03: Executive Summary – Chart on Global Market Characteristics
• Exhibit 04: Executive Summary – Chart on Market by Geography
• Exhibit 05: Executive Summary – Chart on Market Segmentation by Route of Administration
• Exhibit 06: Executive Summary – Chart on Market Segmentation by Action Mechanism
• Exhibit 07: Executive Summary – Chart on Incremental Growth
• Exhibit 08: Executive Summary – Data Table on Incremental Growth
• Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem
• Exhibit 10: Parent market
• Exhibit 11: Market Characteristics

3 Market Sizing

• 3.1 Market definition
• Exhibit 12: Offerings of vendors included in the market definition

• 3.2 Market segment analysis 
• Exhibit 13: Market segments

• 3.3 Market size 2022

• 3.4 Market outlook: Forecast for 2022-2027 
• Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
• Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
• Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
• Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size

• 4.1 Global Pulmonary Arterial Hypertension Drugs Market 2017 - 2021 
• Exhibit 18: Historic Market Size – Data Table on Global Pulmonary Arterial Hypertension Drugs Market 2017 - 2021 ($ million)

• 4.2 Route of Administration Segment Analysis 2017 - 2021 
• Exhibit 19: Historic Market Size – Route of Administration Segment 2017 - 2021 ($ million)

• 4.3 Action Mechanism Segment Analysis 2017 - 2021 
• Exhibit 20: Historic Market Size – Action Mechanism Segment 2017 - 2021 ($ million)

• 4.4 Geography Segment Analysis 2017 - 2021 
• Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ million)

• 4.5 Country Segment Analysis 2017 - 2021 
• Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ million)

5 Five Forces Analysis

• 5.1 Five forces summary
• Exhibit 23: Five forces analysis - Comparison between 2022 and 2027

• 5.2 Bargaining power of buyers 
• Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027

• 5.3 Bargaining power of suppliers 
• Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027

• 5.4 Threat of new entrants 
• Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027

• 5.5 Threat of substitutes 
• Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027

• 5.6 Threat of rivalry
• Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027

• 5.7 Market condition
• Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

6 Market Segmentation by Route of Administration

• 6.1 Market segments
• Exhibit 30: Chart on Route of Administration - Market share 2022-2027 (%)
• Exhibit 31: Data Table on Route of Administration - Market share 2022-2027 (%)

• 6.2 Comparison by Route of Administration 
• Exhibit 32: Chart on Comparison by Route of Administration
• Exhibit 33: Data Table on Comparison by Route of Administration

• 6.3 Oral - Market size and forecast 2022-2027 
• Exhibit 34: Chart on Oral - Market size and forecast 2022-2027 ($ million)
• Exhibit 35: Data Table on Oral - Market size and forecast 2022-2027 ($ million)
• Exhibit 36: Chart on Oral - Year-over-year growth 2022-2027 (%)
• Exhibit 37: Data Table on Oral - Year-over-year growth 2022-2027 (%)

• 6.4 Injectable - Market size and forecast 2022-2027 
• Exhibit 38: Chart on Injectable - Market size and forecast 2022-2027 ($ million)
• Exhibit 39: Data Table on Injectable - Market size and forecast 2022-2027 ($ million)
• Exhibit 40: Chart on Injectable - Year-over-year growth 2022-2027 (%)
• Exhibit 41: Data Table on Injectable - Year-over-year growth 2022-2027 (%)

• 6.5 Inhalation - Market size and forecast 2022-2027 
• Exhibit 42: Chart on Inhalation - Market size and forecast 2022-2027 ($ million)
• Exhibit 43: Data Table on Inhalation - Market size and forecast 2022-2027 ($ million)
• Exhibit 44: Chart on Inhalation - Year-over-year growth 2022-2027 (%)
• Exhibit 45: Data Table on Inhalation - Year-over-year growth 2022-2027 (%)

• 6.6 Market opportunity by Route of Administration 
• Exhibit 46: Market opportunity by Route of Administration ($ million)
• Exhibit 47: Data Table on Market opportunity by Route of Administration ($ million)

7 Market Segmentation by Action Mechanism

• 7.1 Market segments
• Exhibit 48: Chart on Action Mechanism - Market share 2022-2027 (%)
• Exhibit 49: Data Table on Action Mechanism - Market share 2022-2027 (%)

• 7.2 Comparison by Action Mechanism 
• Exhibit 50: Chart on Comparison by Action Mechanism
• Exhibit 51: Data Table on Comparison by Action Mechanism

• 7.3 Prostacyclin analogs - Market size and forecast 2022-2027 
• Exhibit 52: Chart on Prostacyclin analogs - Market size and forecast 2022-2027 ($ million)
• Exhibit 53: Data Table on Prostacyclin analogs - Market size and forecast 2022-2027 ($ million)
• Exhibit 54: Chart on Prostacyclin analogs - Year-over-year growth 2022-2027 (%)
• Exhibit 55: Data Table on Prostacyclin analogs - Year-over-year growth 2022-2027 (%)

• 7.4 Endothelin receptor antagonists (ERAs) - Market size and forecast 2022-2027
• Exhibit 56: Chart on Endothelin receptor antagonists (ERAs) - Market size and forecast 2022-2027 ($ million)
• Exhibit 57: Data Table on Endothelin receptor antagonists (ERAs) - Market size and forecast 2022-2027 ($ million)
• Exhibit 58: Chart on Endothelin receptor antagonists (ERAs) - Year-over-year growth 2022-2027 (%)
• Exhibit 59: Data Table on Endothelin receptor antagonists (ERAs) - Year-over-year growth 2022-2027 (%)

• 7.5 Phosphodiesterase (PDE) inhibitors - Market size and forecast 2022-2027 
• Exhibit 60: Chart on Phosphodiesterase (PDE) inhibitors - Market size and forecast 2022-2027 ($ million)
• Exhibit 61: Data Table on Phosphodiesterase (PDE) inhibitors - Market size and forecast 2022-2027 ($ million)
• Exhibit 62: Chart on Phosphodiesterase (PDE) inhibitors - Year-over-year growth 2022-2027 (%)
• Exhibit 63: Data Table on Phosphodiesterase (PDE) inhibitors - Year-over-year growth 2022-2027 (%)

• 7.6 Soluble guanylate cyclase stimulators (SGCSs) - Market size and forecast 2022-2027
• Exhibit 64: Chart on Soluble guanylate cyclase stimulators (SGCSs) - Market size and forecast 2022-2027 ($ million)
• Exhibit 65: Data Table on Soluble guanylate cyclase stimulators (SGCSs) - Market size and forecast 2022-2027 ($ million)
• Exhibit 66: Chart on Soluble guanylate cyclase stimulators (SGCSs) - Year-over-year growth 2022-2027 (%)
• Exhibit 67: Data Table on Soluble guanylate cyclase stimulators (SGCSs) - Year-over-year growth 2022-2027 (%)

• 7.7 Market opportunity by Action Mechanism 
• Exhibit 68: Market opportunity by Action Mechanism ($ million)
• Exhibit 69: Data Table on Market opportunity by Action Mechanism ($ million)

8 Customer Landscape

• 8.1 Customer landscape overview 
• Exhibit 70: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

• 9.1 Geographic segmentation 
• Exhibit 71: Chart on Market share by geography 2022-2027 (%)
• Exhibit 72: Data Table on Market share by geography 2022-2027 (%)

• 9.2 Geographic comparison 
• Exhibit 73: Chart on Geographic comparison
• Exhibit 74: Data Table on Geographic comparison

• 9.3 North America - Market size and forecast 2022-2027 
• Exhibit 75: Chart on North America - Market size and forecast 2022-2027 ($ million)
• Exhibit 76: Data Table on North America - Market size and forecast 2022-2027 ($ million)
• Exhibit 77: Chart on North America - Year-over-year growth 2022-2027 (%)
• Exhibit 78: Data Table on North America - Year-over-year growth 2022-2027 (%)

• 9.4 Europe - Market size and forecast 2022-2027 
• Exhibit 79: Chart on Europe - Market size and forecast 2022-2027 ($ million)
• Exhibit 80: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
• Exhibit 81: Chart on Europe - Year-over-year growth 2022-2027 (%)
• Exhibit 82: Data Table on Europe - Year-over-year growth 2022-2027 (%)

• 9.5 Asia - Market size and forecast 2022-2027 
• Exhibit 83: Chart on Asia - Market size and forecast 2022-2027 ($ million)
• Exhibit 84: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
• Exhibit 85: Chart on Asia - Year-over-year growth 2022-2027 (%)
• Exhibit 86: Data Table on Asia - Year-over-year growth 2022-2027 (%)

• 9.6 Rest of World (ROW) - Market size and forecast 2022-2027 
• Exhibit 87: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
• Exhibit 88: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
• Exhibit 89: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
• Exhibit 90: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)

• 9.7 US - Market size and forecast 2022-2027 
• Exhibit 91: Chart on US - Market size and forecast 2022-2027 ($ million)
• Exhibit 92: Data Table on US - Market size and forecast 2022-2027 ($ million)
• Exhibit 93: Chart on US - Year-over-year growth 2022-2027 (%)
• Exhibit 94: Data Table on US - Year-over-year growth 2022-2027 (%)

• 9.8 UK - Market size and forecast 2022-2027 
• Exhibit 95: Chart on UK - Market size and forecast 2022-2027 ($ million)
• Exhibit 96: Data Table on UK - Market size and forecast 2022-2027 ($ million)
• Exhibit 97: Chart on UK - Year-over-year growth 2022-2027 (%)
• Exhibit 98: Data Table on UK - Year-over-year growth 2022-2027 (%)

• 9.9 Germany - Market size and forecast 2022-2027 
• Exhibit 99: Chart on Germany - Market size and forecast 2022-2027 ($ million)
• Exhibit 100: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
• Exhibit 101: Chart on Germany - Year-over-year growth 2022-2027 (%)
• Exhibit 102: Data Table on Germany - Year-over-year growth 2022-2027 (%)

• 9.10 Canada - Market size and forecast 2022-2027 
• Exhibit 103: Chart on Canada - Market size and forecast 2022-2027 ($ million)
• Exhibit 104: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
• Exhibit 105: Chart on Canada - Year-over-year growth 2022-2027 (%)
• Exhibit 106: Data Table on Canada - Year-over-year growth 2022-2027 (%)

• 9.11 Japan - Market size and forecast 2022-2027 
• Exhibit 107: Chart on Japan - Market size and forecast 2022-2027 ($ million)
• Exhibit 108: Data Table on Japan - Market size and forecast 2022-2027 ($ million)
• Exhibit 109: Chart on Japan - Year-over-year growth 2022-2027 (%)
• Exhibit 110: Data Table on Japan - Year-over-year growth 2022-2027 (%)

• 9.12 Market opportunity by geography 
• Exhibit 111: Market opportunity by geography ($ million)
• Exhibit 112: Data Tables on Market opportunity by geography ($ million)

10 Drivers, Challenges, and Trends

• 10.1 Market drivers

• 10.2 Market challenges

• 10.3 Impact of drivers and challenges 
• Exhibit 113: Impact of drivers and challenges in 2022 and 2027

• 10.4 Market trends

11 Vendor Landscape

• 11.1 Overview

• 11.2 Vendor landscape
• Exhibit 114: Overview on Criticality of inputs and Factors of differentiation

• 11.3 Landscape disruption
• Exhibit 115: Overview on factors of disruption

• 11.4 Industry risks
• Exhibit 116: Impact of key risks on business

12 Vendor Analysis

• 12.1 Vendors covered
• Exhibit 117: Vendors covered

• 12.2 Market positioning of vendors 
• Exhibit 118: Matrix on vendor position and classification

• 12.3 Aerami Therapeutics Holdings Inc. 
• Exhibit 119: Aerami Therapeutics Holdings Inc. - Overview
• Exhibit 120: Aerami Therapeutics Holdings Inc. - Product / Service
• Exhibit 121: Aerami Therapeutics Holdings Inc. - Key offerings

• 12.4 Asklepion Pharmaceuticals LLC 
• Exhibit 122: Asklepion Pharmaceuticals LLC - Overview
• Exhibit 123: Asklepion Pharmaceuticals LLC - Product / Service
• Exhibit 124: Asklepion Pharmaceuticals LLC - Key offerings

• 12.5 AstraZeneca Plc
• Exhibit 125: AstraZeneca Plc - Overview
• Exhibit 126: AstraZeneca Plc - Product / Service
• Exhibit 127: AstraZeneca Plc - Key news
• Exhibit 128: AstraZeneca Plc - Key offerings

• 12.6 Bayer AG
• Exhibit 129: Bayer AG - Overview
• Exhibit 130: Bayer AG - Business segments
• Exhibit 131: Bayer AG - Key news
• Exhibit 132: Bayer AG - Key offerings
• Exhibit 133: Bayer AG - Segment focus

• 12.7 Daiichi Sankyo Co. Ltd. 
• Exhibit 134: Daiichi Sankyo Co. Ltd. - Overview
• Exhibit 135: Daiichi Sankyo Co. Ltd. - Business segments
• Exhibit 136: Daiichi Sankyo Co. Ltd. - Key news
• Exhibit 137: Daiichi Sankyo Co. Ltd. - Key offerings
• Exhibit 138: Daiichi Sankyo Co. Ltd. - Segment focus

• 12.8 Eiger BioPharmaceuticals Inc. 
• Exhibit 139: Eiger BioPharmaceuticals Inc. - Overview
• Exhibit 140: Eiger BioPharmaceuticals Inc. - Product / Service
• Exhibit 141: Eiger BioPharmaceuticals Inc. - Key offerings

• 12.9 Gilead Sciences Inc.
• Exhibit 142: Gilead Sciences Inc. - Overview
• Exhibit 143: Gilead Sciences Inc. - Product / Service
• Exhibit 144: Gilead Sciences Inc. - Key news
• Exhibit 145: Gilead Sciences Inc. - Key offerings

• 12.10 GlaxoSmithKline Plc
• Exhibit 146: GlaxoSmithKline Plc - Overview
• Exhibit 147: GlaxoSmithKline Plc - Business segments
• Exhibit 148: GlaxoSmithKline Plc - Key news
• Exhibit 149: GlaxoSmithKline Plc - Key offerings
• Exhibit 150: GlaxoSmithKline Plc - Segment focus

• 12.11 Johnson and Johnson Services Inc. 
• Exhibit 151: Johnson and Johnson Services Inc. - Overview
• Exhibit 152: Johnson and Johnson Services Inc. - Business segments
• Exhibit 153: Johnson and Johnson Services Inc. - Key news
• Exhibit 154: Johnson and Johnson Services Inc. - Key offerings
• Exhibit 155: Johnson and Johnson Services Inc. - Segment focus

• 12.12 Lupin Ltd.
• Exhibit 156: Lupin Ltd. - Overview
• Exhibit 157: Lupin Ltd. - Product / Service
• Exhibit 158: Lupin Ltd. - Key news
• Exhibit 159: Lupin Ltd. - Key offerings

• 12.13 Merck and Co. Inc.
• Exhibit 160: Merck and Co. Inc. - Overview
• Exhibit 161: Merck and Co. Inc. - Business segments
• Exhibit 162: Merck and Co. Inc. - Key news
• Exhibit 163: Merck and Co. Inc. - Key offerings
• Exhibit 164: Merck and Co. Inc. - Segment focus

• 12.14 Novartis AG
• Exhibit 165: Novartis AG - Overview
• Exhibit 166: Novartis AG - Business segments
• Exhibit 167: Novartis AG - Key offerings
• Exhibit 168: Novartis AG - Segment focus

• 12.15 Pfizer Inc.
• Exhibit 169: Pfizer Inc. - Overview
• Exhibit 170: Pfizer Inc. - Product / Service
• Exhibit 171: Pfizer Inc. - Key news
• Exhibit 172: Pfizer Inc. - Key offerings

• 12.16 Teva Pharmaceutical Industries Ltd. 
• Exhibit 173: Teva Pharmaceutical Industries Ltd. - Overview
• Exhibit 174: Teva Pharmaceutical Industries Ltd. - Business segments
• Exhibit 175: Teva Pharmaceutical Industries Ltd. - Key news
• Exhibit 176: Teva Pharmaceutical Industries Ltd. - Key offerings
• Exhibit 177: Teva Pharmaceutical Industries Ltd. - Segment focus

• 12.17 United Therapeutics Corp. 
• Exhibit 178: United Therapeutics Corp. - Overview
• Exhibit 179: United Therapeutics Corp. - Product / Service
• Exhibit 180: United Therapeutics Corp. - Key offerings

13 Appendix

• 13.1 Scope of the report

• 13.2 Inclusions and exclusions checklist 
• Exhibit 181: Inclusions checklist
• Exhibit 182: Exclusions checklist

• 13.3 Currency conversion rates for US$ 
• Exhibit 183: Currency conversion rates for US$

• 13.4 Research methodology
• Exhibit 184: Research methodology
• Exhibit 185: Validation techniques employed for market sizing
• Exhibit 186: Information sources

• 13.5 List of abbreviations 
• Exhibit 187: List of abbreviations

About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/

SOURCE Technavio